{"id":18403,"date":"2021-07-08T08:45:52","date_gmt":"2021-07-08T06:45:52","guid":{"rendered":"https:\/\/idibell.cat\/?p=18403"},"modified":"2021-07-08T08:48:45","modified_gmt":"2021-07-08T06:48:45","slug":"un-nou-estudi-defineix-una-predisposicio-epigenetica-a-patir-leucemia-o-limfoma-per-la-infeccio-del-virus-htlv-1","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2021\/07\/un-nou-estudi-defineix-una-predisposicio-epigenetica-a-patir-leucemia-o-limfoma-per-la-infeccio-del-virus-htlv-1\/","title":{"rendered":"Un nou estudi defineix una predisposici\u00f3 epigen\u00e8tica a patir leuc\u00e8mia o limfoma per la infecci\u00f3 del virus HTLV-1"},"content":{"rendered":"

El virus limfotr\u00f2fic hum\u00e0 de c\u00e8l\u00b7lules T tipus 1 (HTLV-1) \u00e9s un virus oncog\u00e8nic que entre altres malalties causa la leuc\u00e8mia\/limfoma \u00a0de c\u00e8l\u00b7lules T de l’adult (ATL) i la parapar\u00e8sia esp\u00e0stica tropical (HAM\/TSP). Aquestes malalties es desenvolupen en el 2-5% de persones portadores del virus i encara es desconeixen els factors gen\u00e8tics, epigen\u00e8tics i\/o ambientals que influeixen en la seva aparici\u00f3.<\/p>\n

El virus HTLV-1 es caracteritza per tenir un per\u00edode de lat\u00e8ncia, en el qual el pacient ja \u00e9s portador del virus per\u00f2 encara no ha desenvolupat cap s\u00edmptoma, particularment llarg, generalment d’entre 20 i 40 anys. Estudis previs suggereixen que durant aquest per\u00edode de lat\u00e8ncia es van acumulant alteracions gen\u00e8tiques indu\u00efdes pel virus que poden donar lloc als processos oncol\u00f2gics anteriorment mencionats.<\/p>\n

Un estudi publicat al Molecular Cancer<\/em> <\/a>que ha comptat amb la participaci\u00f3 de la Dra. Lourdes Farr\u00e9, investigadora principal del grup de recerca en Quimioresist\u00e8ncia Tumoral i Estromal de l’IDIBELL i de l’ICO, ha analitzat el genoma de m\u00e9s de 400 mostres d’individus portadors del virus HTLV-1, incloent-hi pacients amb ATL, HAM\/TSO i portadors asimptom\u00e0tics. Els investigadors han observat que els pacients amb ATL presenten alteracions epigen\u00e8tiques en el gen FHIT que no es troben en els pacients asimptom\u00e0tics o amb HAM\/TSP<\/strong>.<\/p>\n

El gen FHIT \u00e9s un gen supressor de tumors que actua com a cuidador del genoma. Aquest gen codifica per una prote\u00efna que regula la reparaci\u00f3 de l’ADN i prev\u00e9 que les seves alteracions puguin resultar malignes. El silenciament o afectaci\u00f3 d’aquest gen \u00e9s clau en el desenvolupament de molts c\u00e0ncers.<\/p>\n

En els pacients amb ATL que presenten l’alteraci\u00f3 epigen\u00e8tica descrita, aquesta \u00e9s present tant a les c\u00e8l\u00b7lules infectades com a les no infectades. Aquests resultats suggereixen que aquesta modificaci\u00f3 podria ser de naixement i no indu\u00efda pel virus, i que per tant, representaria una marca preexistent que predisposaria al desenvolupament de l’ATL<\/strong>.<\/p>\n

Aquests descobriments tenen importants implicacions cl\u00edniques que obren la possibilitat a detectar preco\u00e7ment aquells portadors de HTLV-1 que tenen m\u00e9s possibilitats de desenvolupar ATL. Aix\u00f2 permetria implementar noves estrat\u00e8gies de seguiment dels pacients i realitzar intervencions primerenques.<\/p>\n

 <\/p>\n

 <\/p>\n

L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n

L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Un estudi, amb participaci\u00f3 de l\u2019IDIBELL i de l\u2019ICO, publicat al Molecular Cancer, ha descrit que aquelles persones que presenten alteracions epigen\u00e8tiques en el gen supressor de tumors FHIT tenen m\u00e9s predisposici\u00f3 a desenvolupar la malaltia.<\/p>\n","protected":false},"author":8,"featured_media":18404,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332,447,452,346],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-12 05:41:59","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/18403"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=18403"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/18403\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/18404"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=18403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=18403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=18403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}